Advertisement
News
Advertisement

AVEO submits kidney cancer drug to FDA

Fri, 09/28/2012 - 12:00am
Mass High Tech: The Journal of New England Technology

AVEO Oncology (Nasdaq: AVEO) and its Japanese partner Astellas Pharma, have submitted kidney cancer drug candidate tivozanib to the U.S. Food and Drug Administration.

In advance of the submission, Cambridge, Mass.-based AVEO has been beefing up its staff, and in May, inked a deal for a new, larger headquarters.

If approved, it would be the first drug on the market developed by AVEO. The companies are seeking approval for treatment of patients with advanced renal cell carcinoma.

Topics

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading